Prof. Thomas Müller

Department of Neurology

St. Joseph Hospital Berlin-Weißensee, Germam

Email: th.mueller@alexius.de, thomas.mueller@ruhr-uni-bochum.de

Qualifications

2009 Consultant Neurology/Psychiatry, St Joseph Berlin Tempelhof

2002 Member of the Faculty, Neuroscience of the Ruhr-University of Bochum

1996 Senior physician, University lecturer

Publications (Selected)

1. Placebo influences on dyskinesia in Parkinson's disease. Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Olanow CW, Rascol O, Russ H. Movement Disorders 2008; 23(5): 700-707.
2. Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease. Müller T, Muhlack S. Journal of Neural Transmission 2008; 115(6): 851-855.
3. A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson's disease patients. Wahl C, Kautzmann S, Krebiehl G, Strauss K, Woitalla D, Müller T, Bauer P, Riess O and Krüger R. Journal of Neural Transmission 2008; 115(8): 1141-1148.
4. Entacapone improves absorption of a co-administered salt in patients with Parkinson’s disease. Müller T, Woitalla D, Goetze O, Erdmann C. Movement Disorders 2008; 23(10): 1458-1461.
5. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T, Advance Study Group. Archives of Neurology 2008; 65(5): 577-583.
6. Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, Schielke E, Schmutzhard E, de Gans J, Chung CH, Luntz S, Hacke W, Meyding-Lamadé U, and the GACHE Investigators. BMC Neurology 2008; 8: 40.
7. Increase of relapse rate during assisted reproduction technique in patients with multiple sclerosis. Hellwig K, Schimrigk S, Beste C, Müller T, Gold R. European Neurology 2009; 61(2): 65-68.
8. Cysteine elevation in Levodopa treated patients with Parkinson’s disease. Müller T, Kuhn W. Movement Disorders 2009; 24(6): 929-932.
9. Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control. Willemssen R, Falkenstein M, Schwarz M, Müller T, Beste C. Neurobiology of Aging Epub 2009, DOI: 10.1016/j.neurobiolaging.2009.02.002.
10. Homocysteine levels after acute levodopa intake in patients with Parkinson’s disease. Müller T, Kuhn W. Movement Disorders 2009; 24(9): 1339-1343.
11. Response monitoring in de novo patients with Parkinson's disease. Willemsen R, Müller T, Schwarz M, Falkenstein M, Beste C. Plos One 2009; 4(3): e4898.
12. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Bensimon G, Ludolph A, Agid Y, Vildaihet M, Payan C, Leigh PN, NNIPS Study Group. Brain 2009; 132: 156-171.
13. Peripheral COMT inhibition prevents levodopa associated homocysteine increase. Müller T, Muhlack S. Journal of Neural Transmission 2009; 116(10): 1253-1256.
14. Tolcapone ist wirksam, sicher und gut vertrglich: eine offene, beobachtende Studie. Müller T, Fischer G. Aktuelle Neurologie 2009; 36: 499-505.
15. Diadochokinetic movements differ between patients with Parkinson’s disease and controls. Müller T, Harati A. Journal of Neural Transmission 2010; 117(2): 189-195.
16. Effect of exercise on reactivity and motor behavior in patients with Parkinson’s disease. Müller T and Muhlack S. Journal of Neurology, Neurosurgery & Psychiatry 2010; 81: 747-753.